Logo Logo Logo Logo Logo
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • Newsroom
    • Press Releases
    • Media
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT

Press Releases

Investor Relations

Investor Relations

  • Overview
  • Analyst Coverage
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance

Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress

May 4, 2020

Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility

Apr 23, 2020

Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD™ Pivotal Phase 3 Clinical Trial

Apr 16, 2020

Adial Pharmaceuticals Issued Second Patent Covering AD04 as a Treatment for Opioid Use Disorder

Apr 15, 2020

Adial Pharmaceuticals Provides Update on ONWARD™ Phase 3 Pivotal Trial

Apr 9, 2020

Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

Mar 26, 2020

Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19

Mar 17, 2020

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria

Feb 19, 2020

Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat

Feb 14, 2020

Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder

Feb 6, 2020
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...11

    ©Adial Pharmaceuticals 2021